

REFINITIV

DELTA REPORT

10-Q

SBFM - SUNSHINE BIOPHARMA, INC

10-Q - SEPTEMBER 30, 2023 COMPARED TO 10-Q - JUNE 30, 2023

The following comparison report has been automatically generated

TOTAL DELTAS 447

■	CHANGES	108
■	DELETIONS	159
■	ADDITIONS	180

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM **FORM 10-Q**


QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: **June September 30, 2023**

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 001-41282



SUNSHINE BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Colorado

(State of other jurisdiction of incorporation)

20-5566275

(IRS Employer ID No.)

**6500 Trans-Canada Highway
4th Floor
Pointe-Claire, Quebec, Canada H9R 0A5**

(Address of principal executive offices)

(514) 426-6161

(Issuer's Telephone Number)

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of Each Class</u>	<u>Trading Symbol</u>	<u>Name of Each Exchange on Which Registered</u>
Common Stock	SBFM	The NASDAQ Stock Market LLC
Common Stock Purchase Warrants	SBFMW	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for

such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company", and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one)

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
 No

The number of shares of the registrant's common stock, par value \$0.001, issued and outstanding as of **August 10, 2023** **November 13, 2023**, was **25,746,302** **25,678,290** shares.

TABLE OF CONTENTS

	Page
<u>PART I. FINANCIAL INFORMATION</u>	
Item 1. <u>Financial Statements</u>	3
<u>Consolidated Unaudited Balance Sheet as of June 30, 2023 September 30, 2023 (Unaudited) and December 31, 2022</u>	3
<u>Consolidated Unaudited Statements of Operations for the Six Nine Months Ended June 30, 2023 September 30, 2023 and 2022 (Unaudited)</u>	4
<u>Consolidated Unaudited Statements of Cash Flows for the Six Nine Months Ended June 30, 2023 September 30, 2023 and 2022 (Unaudited)</u>	5
<u>Consolidated Unaudited Statement of Shareholders' Equity for the Six Nine Months Ended June 30, 2023 September 30, 2023 and 2022 (Unaudited)</u>	6
<u>Notes to Unaudited Consolidated Financial Statements</u>	7
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	16
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	24
Item 4. <u>Controls and Procedures</u>	24
<u>PART II. OTHER INFORMATION</u>	
Item 1. <u>Legal Proceedings</u>	25
Item 1A. <u>Risk Factors</u>	25
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	25
Item 3. <u>Defaults Upon Senior Securities</u>	25
Item 4. <u>Mine Safety Disclosures</u>	25
Item 5. <u>Other Information</u>	25
Item 6. <u>Exhibits</u>	25
<u>Signatures</u>	26

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Sunshine Biopharma, Inc. **Consolidated Balance Sheets**

	June 30, 2023	December 31, 2022		
	(Unaudited)			
ASSETS				
Current Assets:				
Cash and cash equivalents	\$ 19,729,491	\$ 21,826,437		
Accounts receivable	2,011,308	1,912,153		
Inventory	4,250,887	3,289,945		
Prepaid expenses	107,023	283,799		
Total Current Assets	26,098,709	27,312,334		
Property and equipment	366,684	394,249		
Intangible assets	1,233,570	776,856		
Right-of-use-asset	711,059	760,409		
TOTAL ASSETS	\$ 28,410,022	\$ 29,243,848		
LIABILITIES				
Current Liabilities:				
Accounts payable and accrued expenses	\$ 1,759,789	\$ 2,802,797		
Earnout payable	2,547,831	3,632,000		
Income tax payable	230,581	373,191		
Right-of-use-liability	122,146	123,026		
Total Current Liabilities	4,660,347	6,931,014		
Long-Term Liabilities:				
Deferred tax liability	43,032	43,032		
Right-of-use-liability	596,850	642,232		
Total Long-Term Liabilities	639,882	685,264		
TOTAL LIABILITIES	5,300,229	7,616,278		
SHAREHOLDERS' EQUITY				
Preferred Stock, Series B \$0.10 par value per share; 1,000,000 shares authorized; 10,000 shares issued and outstanding	1,000	1,000		

Common Stock, \$0.001 par value per share; 3,000,000,000 shares authorized; 25,746,302 and 22,585,632 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively	25,746	22,585
Capital paid in excess of par value	84,422,143	80,841,752
Accumulated comprehensive income	665,056	161,847
Accumulated (Deficit)	(62,004,152)	(59,399,614)
TOTAL SHAREHOLDERS' EQUITY	<u>23,109,793</u>	<u>21,627,570</u>
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	<u>\$ 28,410,022</u>	<u>\$ 29,243,848</u>
	September 30, 2023	December 31, 2022
	(Unaudited)	
ASSETS		
Current Assets:		
Cash and cash equivalents	\$ 18,846,140	\$ 21,826,437
Accounts receivable	2,034,119	1,912,153
Inventory	4,517,044	3,289,945
Prepaid expenses	37,556	283,799
Total Current Assets	<u>25,434,859</u>	<u>27,312,334</u>
Property and equipment	334,922	394,249
Intangible assets	1,216,207	776,856
Right-of-use-asset	664,296	760,409
TOTAL ASSETS	<u>\$ 27,650,284</u>	<u>\$ 29,243,848</u>
LIABILITIES		
Current Liabilities:		
Accounts payable and accrued expenses	\$ 2,220,870	\$ 2,802,797
Earnout payable	2,547,831	3,632,000
Income tax payable	201,541	373,191
Right-of-use-liability	117,840	123,026
Total Current Liabilities	<u>5,088,082</u>	<u>6,931,014</u>
Long-Term Liabilities:		
Deferred tax liability	43,032	43,032
Right-of-use-liability	555,687	642,232
Total Long-Term Liabilities	<u>598,719</u>	<u>685,264</u>
TOTAL LIABILITIES	<u>5,686,801</u>	<u>7,616,278</u>
SHAREHOLDERS' EQUITY		

Preferred Stock, Series B \$0.10 par value per share; 1,000,000 shares authorized; 10,000 Shares issued and outstanding	1,000	1,000
Common Stock, \$0.001 par value per share; 3,000,000,000 shares authorized; 25,678,290 and 22,585,632 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	25,678	22,585
Capital paid in excess of par value	84,387,890	80,841,752
Accumulated comprehensive income	204,549	161,847
Accumulated (Deficit)	(62,655,634)	(59,399,614)
TOTAL SHAREHOLDERS' EQUITY	21,963,483	21,627,570
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 27,650,284	\$ 29,243,848

The accompanying notes are an integral part of these unaudited financial statements

Sunshine Biopharma, Inc.

Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

	3 Months Ended June 30,		6 Months Ended June 30,	
	2023	2022	2023	2022
Sales:	\$ 5,560,865	\$ 150,307	\$ 10,454,918	\$ 272,952
Cost of sales	3,608,118	74,683	6,674,049	134,528
Gross profit	<u>1,952,747</u>	<u>75,624</u>	<u>3,780,869</u>	<u>138,424</u>
General and Administrative Expenses:				
Accounting	75,281	41,060	245,031	114,860
Consulting	392,454	101,683	524,069	107,181
Director fees	100,000	50,000	200,000	50,000
Legal	145,815	112,360	259,572	256,919
Marketing	133,177	87,680	261,090	182,720
Office	395,385	90,407	877,843	372,912
R&D	368,565	45,943	801,490	407,595
Salaries	1,200,167	240,000	3,200,424	560,000
Taxes	96,649	–	160,367	–
Depreciation	34,877	2,287	69,587	5,397
Total General and Administrative Expenses	<u>2,942,370</u>	<u>771,420</u>	<u>6,599,473</u>	<u>2,057,584</u>
(Loss) from operations	<u>(989,623)</u>	<u>(695,796)</u>	<u>(2,818,604)</u>	<u>(1,919,160)</u>
Other Income (Expense):				
Foreign exchange	(261)	29	(246)	20
Interest income	203,049	146,043	416,930	146,046
Debt release	–	10,852	–	10,852
Interest expense	(27,596)	–	(68,671)	(12,864)
Total Other Income (Expense)	<u>175,192</u>	<u>156,924</u>	<u>348,013</u>	<u>144,054</u>
Net (loss) before income taxes	(814,431)	(538,872)	(2,470,591)	(1,775,106)
Provision for income taxes	(87,677)	–	(133,947)	–
Net (Loss)	<u>\$ (902,108)</u>	<u>\$ (538,872)</u>	<u>\$ (2,604,538)</u>	<u>\$ (1,775,106)</u>
Gain (Loss) from foreign exchange translation	492,049	(12,645)	503,209	(11,638)
Comprehensive (Loss)	<u>\$ (410,059)</u>	<u>\$ (551,517)</u>	<u>\$ (2,101,329)</u>	<u>\$ (1,786,744)</u>

Basic (Loss) per common share	\$ (0.02)	\$ (0.03)	\$ (0.09)	\$ (0.18)
Weighted average common shares outstanding (Basic and Diluted)	25,350,263	15,849,518	23,827,205	9,691,625
	3 Months Ended September 30,	9 Months Ended September 30,		
	2023	2022	2023	2022
Sales	\$ 5,957,668	\$ 132,808	\$ 16,412,586	\$ 405,760
Cost of sales	3,967,412	65,783	10,641,461	200,311
Gross profit	1,990,256	67,025	5,771,125	205,449
General and Administrative Expenses:				
Accounting	56,350	122,913	301,381	237,773
Consulting	221,781	162,852	745,850	270,033
Director fees	100,000	100,000	300,000	200,000
Legal	133,302	146,467	392,874	403,386
Marketing	241,897	217,666	502,987	400,386
Office	544,215	76,818	1,422,058	449,730
R&D	238,012	362,500	1,039,502	770,095
Salaries	1,144,377	595,000	4,344,801	1,105,000
Taxes	52,586	–	212,953	–
Depreciation	37,210	789	106,797	6,186
Total General and Administrative Expenses:	2,769,730	1,785,005	9,369,203	3,842,589
(Loss) from operations	(779,474)	(1,717,980)	(3,598,078)	(3,637,140)
Other Income (Expense):				
Foreign exchange	40	25	(206)	45
Interest income	207,431	260,938	624,361	406,984
Debt release	–	–	–	10,852
Interest expense	(38,527)	(2)	(107,198)	(12,866)
Total Other Income (Expense)	168,944	260,961	516,957	405,015
Net (loss) before income taxes	(610,530)	(1,457,019)	(3,081,121)	(3,232,125)
Provision for income taxes	(40,952)	–	(174,899)	–
Net (Loss)	\$ (651,482)	\$ (1,457,019)	\$ (3,256,020)	\$ (3,232,125)
Gain (Loss) from foreign exchange translation	(460,507)	(45,126)	42,702	(56,764)
Comprehensive (Loss)	\$ (1,111,989)	\$ (1,502,145)	\$ (3,213,318)	\$ (3,288,889)

Basic (Loss) per common share	\$ (0.04)	\$ (0.08)	\$ (0.133)	\$ (0.26)
-------------------------------	-----------	-----------	------------	-----------

Weighted Average Common Shares Outstanding (Basic and Diluted)	25,690,449	18,885,632	24,507,122	12,789,733
---	------------	------------	------------	------------

The accompanying notes are an integral part of these unaudited financial statements

Sunshine Biopharma, Inc.
Consolidated Statements of Cash Flows (Unaudited)

	June 30, 2023	June 30, 2022
Cash Flows From Operating Activities:		
Net (Loss)	\$ (2,604,538)	\$ (1,775,106)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	69,594	5,397
Foreign exchange	-	(20)
Debt release	-	(10,852)
Accounts receivable	(55,160)	7,774
Inventory	(885,243)	(99,721)
Prepaid expenses	182,852	(18,937)
Accounts payable and accrued expenses	(1,103,502)	61,742
Income tax payable	(147,980)	-
Interest payable	(1,084,169)	(48,287)
Net Cash Flows (Used) in Operations	(5,628,146)	(1,878,010)
Cash Flows From Investing Activities:		
Reduction in Right-of-use asset	66,846	-
Purchase of intangible assets	(17,645)	-
Purchase of equipment	(454,980)	-
Net Cash Flows (Used) in Investing activities	(405,779)	-
Cash Flows From Financing Activities:		
Common stock issued	4,089,208	43,560,363
Exercise of warrants	1,156	-
Purchase of treasury stock	(506,822)	(99,000)
Lease liability	(63,870)	-
Payments of notes payable	-	(1,900,000)
Net Cash Flows Provided by Financing Activities	3,519,672	41,561,363
Cash and Cash Equivalents at Beginning of Period		
Net increase (decrease) in cash and cash equivalents	21,826,437	2,045,167
Effect of exchange rate changes on cash	(2,514,253)	39,683,353
Foreign currency translation adjustment	9	(12,383)
Cash and Cash Equivalents at End of Period	\$ 19,729,491	\$ 41,727,775
Supplementary Disclosure Of Cash Flow Information:		

Cash paid for interest	\$ -	\$ 61,151
Cash paid for income taxes	\$ -	\$ -
	September 30, 2023	September 30, 2022
Cash Flows From Operating Activities:		
Net (Loss)	\$ (3,256,020)	\$ (3,232,125)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	106,794	6,186
Foreign exchange	(374)	45
Debt release	-	(10,852)
Accounts receivable	(118,482)	7,776
Inventory	(1,221,112)	(163,991)
Prepaid expenses	247,977	2,235
Accounts payable and accrued expenses	(587,973)	437,267
Income tax payable	(172,076)	-
Interest payable	(1,084,169)	(48,287)
Net Cash Flows (Used) in Operations	<u>(6,085,435)</u>	<u>(3,001,746)</u>
Cash Flows From Investing Activities:		
Reduction in Right-of-use asset	97,498	-
Purchase of intangible assets	(19,804)	-
Purchase of equipment	(464,614)	-
Net Cash Flows (Used) in Investing Activities	<u>(386,920)</u>	<u>-</u>
Cash Flows From Financing Activities:		
Common stock issued	4,089,218	43,560,363
Exercise of warrants	1,156	-
Purchase of treasury stock	(541,143)	(99,000)
Lease liability	(93,125)	-
Payments of notes payable	-	(1,900,000)
Net Cash Flows Provided by Financing Activities	<u>3,456,106</u>	<u>41,561,363</u>
Cash and Cash Equivalents at Beginning of Period		
Net increase (decrease) in cash and cash equivalents	21,826,437	2,045,167
Effect of exchange rate changes on cash	(3,016,249)	38,559,617
Foreign currency translation adjustment	-	(105,617)
Cash and Cash Equivalents at End of Period	<u>\$ 18,846,140</u>	<u>\$ 40,555,931</u>
Supplementary Disclosure of Cash Flow Information:		
Cash paid for interest	\$ -	\$ 61,151

Cash paid for income taxes

\$ - \$ -

The accompanying notes are an integral part of these unaudited financial statements

Sunshine Biopharma, Inc.

Consolidated Statement of Shareholders' Equity (Unaudited)

	Number Of Common Shares Issued	Common Stock	Capital Paid in Excess of Par Value	Number Of Preferred Shares Issued	Preferred Stock	Comprehensive Income	Accumulated Deficit	Total
	Three Month Period Ended September 30, 2023							
Balance at June 30, 2023	25,746,302	\$ 25,746	\$ 84,422,143	10,000	\$ 1,000	\$ 665,056	\$ (62,004,152)	\$ 23,109,793
Repurchase stock	(68,012)	(68)	(34,253)	-	-	-	-	-
Net (loss)	-	-	-	-	-	(460,507)	(651,482)	(1,111,989)
Balance at September 30, 2023	25,678,290	\$ 25,678	\$ 84,387,890	10,000	\$ 1,000	\$ 204,549	\$ (62,655,634)	\$ 21,963,483
Nine Month Period Ended September 30, 2023								
Balance December 31, 2022	22,585,632	\$ 22,585	\$ 80,841,752	10,000	\$ 1,000	\$ 161,847	\$ (59,399,614)	\$ 21,627,570
Repurchase of common stock	(513,723)	(514)	(540,629)	-	-	-	-	-
Common stock and pre- funded warrants issued in a private offering	2,450,000	2,451	4,086,767	-	-	-	-	4,089,218
Exercise of warrants	1,156,381	1,156	-	-	-	-	-	1,156
Net (loss)	-	-	-	-	-	42,702	(3,256,020)	(3,213,318)
Balance at September 30, 2023	25,678,290	\$ 25,678	\$ 84,387,890	10,000	\$ 1,000	\$ 204,549	\$ (62,655,634)	\$ 21,963,483
Three Month Period Ended September 30, 2022								
Balance at June 30, 2022	18,885,632	\$ 18,886	\$ 76,331,451	10,000	\$ 1,000	\$ (34,777)	\$ (34,430,280)	\$ 41,886,280
Net (loss)	-	-	-	-	-	(45,126)	(1,457,019)	(1,502,145)

Balance at September 30, 2022	<u>18,885,632</u>	<u>\$ 18,886</u>	<u>\$ 76,331,451</u>	<u>10,000</u>	<u>\$ 1,000</u>	<u>\$ (79,903)</u>	<u>\$ (35,887,299)</u>	<u>\$ 40,384,135</u>
Nine Month Period Ended September 30, 2022								
Balance								
December 31, 2021	2,595,620	\$ 2,596	\$ 32,787,379	1,000,000	\$ 100,000	\$ (23,139)	\$ (32,655,174)	\$ 211,662
Common stock and pre-funded warrants issued in public offering	6,656,526	6,657	30,360,528	-	-	-	-	30,367,185
Exercise of warrants	9,633,486	9,633	13,183,544	-	-	-	-	13,193,177
Preferred stock purchased from related party	-	-	-	(990,000)	(99,000)	-	-	(99,000)
Net (loss)	-	-	-	-	-	(56,764)	(3,232,125)	(3,288,889)
Balance at September 30, 2022	<u>18,885,632</u>	<u>\$ 18,886</u>	<u>\$ 76,331,451</u>	<u>10,000</u>	<u>\$ 1,000</u>	<u>\$ (79,903)</u>	<u>\$ (35,887,299)</u>	<u>\$ 40,384,135</u>
	Number Of Common Shares Issued	Common Stock	Capital Paid in Excess of Par Value	Number Of Preferred Shares Issued	Preferred Stock	Comprehensive Income	Accumulated Deficit	Total
Three Month Period Ended June 30, 2023								
Balance at March 31, 2023	22,139,921	\$ 22,139	\$ 80,335,376	10,000	\$ 1,000	\$ 173,007	\$ (61,102,044)	\$ 19,429,478
Common stock and pre-funded warrants issued in a private offering	2,450,000	2,451	4,086,767	-	-	-	-	4,089,218
Exercise of warrants	1,156,381	1,156	-	-	-	-	-	1,156
Net (loss)	-	-	-	-	-	492,049	(902,108)	(410,059)
Balance at June 30, 2023	<u>25,746,302</u>	<u>\$ 25,746</u>	<u>\$ 84,422,143</u>	<u>10,000</u>	<u>\$ 1,000</u>	<u>\$ 665,056</u>	<u>\$ (62,004,152)</u>	<u>\$ 23,109,793</u>
Six Month Period Ended June 30, 2023								

Balance at December 31, 2022	22,585,632	\$ 22,585	\$ 80,841,752	10,000	\$ 1,000	\$ 161,847	\$ (59,399,614)	\$ 21,627,570
Repurchased stock	(445,711)	(446)	(506,376)	-	-	-	-	-
Common stock and pre-funded warrants issued in a private offering	2,450,000	2,451	4,086,767	-	-	-	-	4,089,218
Exercise of warrants	1,156,381	1,156	-	-	-	-	-	1,156
Net (loss)	-	-	-	-	-	503,209	(2,604,538)	(2,101,329)
Balance at June 30, 2023	25,746,302	\$ 25,746	\$ 84,422,143	10,000	\$ 1,000	\$ 665,056	\$ (62,004,152)	\$ 23,109,793
Three Month Period Ended June 30, 2022								
Balance at March 31, 2022	7,149,778	\$ 7,150	\$ 47,219,498	10,000	\$ 1,000	\$ (22,132)	\$ (33,891,408)	\$ 13,314,108
Common stock and pre-funded warrants issued in public offering	2,472,820	2,473	16,750,442	-	-	-	-	16,752,915
Exercise of warrants	9,263,034	9,263	12,361,511	-	-	-	-	12,370,774
Net (loss)	-	-	-	-	-	(12,645)	(538,872)	(551,517)
Balance at June 30, 2022	18,885,632	\$ 18,886	\$ 76,331,451	10,000	\$ 1,000	\$ (34,777)	\$ (34,430,280)	\$ 41,886,280
Six Month Period Ended June 30, 2022								
Balance December 31, 2021	2,595,620	\$ 2,596	\$ 32,787,379	1,000,000	\$ 100,000	\$ (23,139)	\$ (32,655,174)	\$ 211,662
Common stock and pre-funded warrants issued in public offering	6,656,526	6,657	30,360,528	-	-	-	-	30,367,185
Exercise of warrants	9,633,486	9,633	13,183,544	-	-	-	-	13,193,177
Preferred stock purchased from related party	-	-	-	(990,000)	(99,000)	-	-	(99,000)
Net (loss)	-	-	-	-	-	(11,638)	(1,775,106)	(1,786,744)

Balance at								
June 30, 2022	<u>18,885,632</u>	<u>\$ 18,886</u>	<u>\$ 76,331,451</u>	<u>10,000</u>	<u>\$ 1,000</u>	<u>\$ (34,777)</u>	<u>\$ (34,430,280)</u>	<u>\$ 41,886,280</u>

The accompanying notes are an integral part of these unaudited financial statements

Sunshine Biopharma, Inc.

Notes to Unaudited Consolidated Financial Statements (Unaudited) For the Six Nine Months Ended June 30, 2023 September 30, 2023 and 2022

Note 1 – Description of Business

The Company was originally incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Effective October 15, 2009, the Company acquired Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. Upon completion of the reverse acquisition transaction, the Company changed its name to Sunshine Biopharma, Inc. and began operating as a pharmaceutical company.

In addition to conducting its own drug development activities, Sunshine Biopharma operates two wholly owned subsidiaries: (i) Nora Pharma Inc. ("Nora Pharma"), a Canadian corporation with a portfolio of pharmaceutical products consisting of 50 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc. ("Sunshine Canada"), a Canadian corporation which develops and sells nonprescription over-the-counter ("OTC") products. In addition to the 51 generic prescription drugs currently on the market in Canada, the Company has 32 additional generic prescription drugs scheduled to be launched in 2024 and 2025 in Canada.

The Company has identified determined that it has two potential reportable segments:

- Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals")
- Nonprescription Over-The-Counter Products ("OTC Products")

Through December 31, 2022 and as of June 30, 2023 September 30, 2023, sales from the Generic Pharmaceuticals segment represent represented approximately 97% of total revenues of the Company while the remaining approximately 3% is 3% was generated from the sale of OTC Products. Based on these results, the Company deems segmentation reporting to be immaterial at June 30, 2023 September 30, 2023.

The Company is not subject to material customer concentration risks as it sells its products directly to pharmacies in several Canadian Provinces. Provincial governments in Canada reimburse patients for their prescription drugs expenditures to various degrees under drug reimbursement programs, making generic drugs prices highly dependent on government regulations which may change over time. The most recent negotiations between the pan-Canadian Pharmaceutical Alliance and the Canadian Generic Pharmaceutical Association have resulted in updated generic pricing for certain products which took effect on October 1, 2023. The updated prices are valid for three years and the agreement contains an option to extend for an additional two years.

The Company currently has 27 additional generic prescription drugs scheduled to be launched later this year and in 2024. In addition, the Company is engaged in the development of the following proprietary drugs:

- (1) Adva-27a, a small chemotherapy molecule for treatment of pancreatic cancer (IND-enabling studies were paused on November 2, 2023 due to unfavorable results. See Note 13 – Subsequent Events)

At inception, Sunshine Biopharma, Inc. held an exclusive license to a new anticancer drug bearing the laboratory name, Adva-27a (the "License Agreement"). In December 2015, the Company acquired all rights to Adva-27a by purchasing PCT/FR2007/000697 and PCT/CA2014/000029 and terminated the License Agreement. Adva-27a is a small chemotherapy molecule targeting pancreatic cancer.

(2) K1.1 mRNA, a lipid nano-particle (LNP) targeted for liver cancer

In June 2021, the Company initiated an R&D project to determine if certain mRNA molecules can be used as anticancer agents. On April 20, 2022, the Company filed a patent application in the United States covering mRNA molecules capable of destroying cancer cells in vitro. The K1.1 lead anticancer mRNA molecule arising from this technology is targeted for liver cancer.

(3) SBFM-PL4, a protease inhibitor for treatment of Coronavirus infections

On May 22, 2020, the Company filed a provisional patent application in the United States for a new treatment for Coronavirus infections. The Company's patent application covers composition subject matter pertaining to small molecules for inhibition of the Coronavirus main protease, Mpro, and the Papain-Like protease, PLpro. The Company's lead Anti-Coronavirus compound arising from these patents bears the laboratory name SBFM-PL4. The Company has been conducting research on this project in collaboration with the University of Arizona and has recently entered into an exclusive worldwide license agreement with the University of Arizona for all of the technology related to the collaboration.

Note 2 – Basis of Presentation

The unaudited financial statements of the Company for the **six** months periods ended **June 30, 2023** **September 30, 2023** and 2022 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The balance sheet information as of December 31, 2022, was derived from the audited financial statements included in the Company's financial statements as of and for the year ended December 31, 2022, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on April 4, 2023. These financial statements should be read in conjunction with that report.

Note 3 – Private Placement

On May 16, 2023, the Company completed a private placement pursuant to a securities purchase agreement with a single **healthcare-focused** institutional investor for gross proceeds of approximately \$5 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The net proceeds received by the Company were \$4,089,218.

In connection with the private placement, the Company issued (i) 2,450,000 shares of common stock, (ii) 3,502,381 pre-funded warrants (the "May Pre-Funded Warrants"), and (iii) 11,904,762 investor warrants (the "May Investor Warrants") to purchase up to 11,904,762 shares of common stock at \$0.59 per share. Each share of common stock and accompanying two May Investor Warrants were sold together at a combined offering price of \$0.84 and each May Pre-Funded Warrant and accompanying two May Investor Warrants were sold together at a combined offering price of \$0.839. The May Pre-Funded Warrants are immediately exercisable at a nominal exercise price of \$0.001, and may be exercised at any time until all of the May Pre-Funded Warrants are exercised in full. The May Investor Warrants which have an exercise price of \$0.59 per share (subject to adjustment as set forth therein), are exercisable upon issuance and will expire five and a half years from the date of issuance. As of September 30, 2023, a total of 1,156,381 May Pre-Funded Warrants and no May Investor Warrants have been exercised. The net proceeds received from the exercise of May Pre-Funded Warrants were \$1,156.

Note 4 – Acquisition of Nora Pharma Inc.

On October 20, 2022, the Company acquired all of the issued and outstanding shares of Nora Pharma Inc. The purchase price for the shares was \$18,860,637 (USD), \$14,346,637(USD) of which was paid in cash (\$14,346,637) and by the remainder was paid through the issuance of 3,700,000 shares of the Company's common stock valued at \$4,514,000 or \$1.22 per share. Nora Pharma sells generic pharmaceutical products in Canada. Nora Pharma's operations are authorized by a Drug Establishment License issued by Health Canada.

The following table summarizes the allocation of the purchase price as of October 20, 2022, the acquisition date using Nora Pharma's balance sheet assets and liabilities:

	\$ 1,358,121	\$ 1,358,121
Accounts receivable	\$ 1,358,121	\$ 1,358,121
Inventory	3,181,916	3,181,916
Intangible assets	659,571	659,571
Equipment & furniture	210,503	210,503
Other assets	1,105,093	1,105,093
Total assets	<u>6,515,204</u>	<u>6,515,204</u>
Liabilities assumed	(5,981,286)	(5,981,286)
Net assets	533,918	533,918
Goodwill	18,326,719	18,326,719
Total Consideration	<u>\$ 18,860,637</u>	<u>\$ 18,860,637</u>

The value of the 3,700,000 common shares issued as part of the consideration paid for Nora Pharma was determined based on the closing market price of the Company's common shares on the acquisition date, October 20, 2022 (\$1.22 per share).

The Company impaired 100% of the goodwill amount in 2022 and plans to depreciate the intangible assets as detailed in Note 5 below.

As part of the consideration paid for Nora Pharma, the Company agreed to a \$5,000,000 CAD (\$3,632,000 USD) earnout amount payable to Mr. Malek Chamoun, the Seller of Nora Pharma. The earnout is payable in the form of twenty (20) payments of \$250,000 CAD for every \$1,000,000 CAD increase in gross sales (as defined in the Purchase Agreement) above Nora Pharma's June 30, 2022 gross sales, provided that his employment with the Company is not terminated pursuant to the Company's Employment Agreement employment agreement with him. The total earnout amount of \$3,632,000 has been recorded as a salary payable. During the six-month nine-month period ended June 30, 2023 September 30, 2023, the Company paid an earn-out amount of \$1,084,169 leaving a balance earn-out to be paid of \$2,547,831 at June 30, 2023 September 30, 2023.

The unaudited financial information in the table below summarizes the combined results of operations of the Company and Nora Pharma for the years ended December 31, 2022 and 2021, on a pro forma basis, as though the two companies had been combined as of January 1, 2021. The unaudited pro forma financial information does not purport to be indicative of the Company's combined results of operations which would have been obtained had the acquisition taken place on January 1, 2021, nor should it be taken as indicative of future consolidated results of operations:

Pro Forma results from acquisition	December	December	December	December
	31, 2022	31, 2021		
Pro Forma Results From Acquisition				
Total revenues	\$ 14,758,115	\$ 7,927,165	\$ 14,758,115	\$ 7,927,165
Net (loss) from operations	\$ (26,192,503)	\$ (2,224,253)	\$ (26,192,503)	\$ (2,224,253)
Net (loss)	\$ (26,164,764)	\$ (12,289,655)	\$ (26,164,764)	\$ (12,289,655)
Basic and fully diluted (loss) per share	\$ (1.74)	\$ (4.70)	\$ (1.74)	\$ (4.70)
Weighted average number of shares outstanding	15,056,097	2,612,061	15,056,097	2,612,061

Note 5 – Intangible Assets

Intangible assets, net, consisted of the following at **June 30, 2023** **September 30, 2023**:

Balance June 30, 2023	\$ 1,233,570
Dossier fee additions	13,905
Balance at September 30, 2023	1,247,475
Less accumulated amortization	(31,268)
Finite-lived intangible assets, net, at September 30, 2023	<u>\$ 1,216,207</u>
Balance December 31, 2022	\$ 776,856
Dossier fee additions	470,619
Balance at September 30, 2023	1,247,475
Less accumulated amortization	(31,268)
Finite-lived intangible assets, net, at September 30, 2023	<u>\$ 1,216,207</u>
Balance at March 31, 2023	\$ 948,240
Dossier fee additions	305,801
Balance at June 30, 2023	1,254,041
Less accumulated amortization	(20,471)
Finite-lived intangible assets net at June 30, 2023	<u>\$ 1,233,570</u>
Balance at December 31, 2022	\$ 776,856
Dossier fee additions	183,760
Balance at March 31, 2023	960,616
Less accumulated amortization	(12,376)
Finite-lived intangible assets net at March 31, 2023	<u>\$ 948,240</u>

Amortization expense for the **three-month** **three months** period ended **March 31, 2023** **September 30, 2023**, and the **three-month** **nine months** period ended **June 30, 2023** **September 30, 2023**, amounted to **\$7,853** **10,797** and **\$8,096** **26,746**, respectively.

As of **June 30 2023**, **September 30, 2023**, estimated amortization expense of the Company's intangible assets for each of the next five years is as follows:

2024	\$ 46,814
2025	46,814
2026	45,611
2027	6,153
2028	1,989

2024	\$ 55,418
2025	55,418
2026	54,240
2027	15,599
2028	7,370

Note 6 – Reverse Stock Splits

Effective February 9, 2022, the Company completed a 1 for 200 reverse split of its common stock. The Company had previously completed two 20 to 1 reverse stock splits, one in 2019 and the other in 2020. The Company's financial statements reflect all three reverse stock splits on a retroactive basis for all periods presented and for all references to common stock, unless specifically stated otherwise.

10

Note 7 – Capital Stock

The Company's authorized capital is comprised of 3,000,000,000 shares of \$0.001 common stock, par value common stock \$0.001, and 30,000,000 shares of \$0.10 par value preferred stock, to have such rights and preferences as the Directors of the Company have or may assign from time to time. As of December 31, 2021 December 31, 2022 and September 30, 2023, the Company had authorized 1,000,000 shares of Series B Preferred Stock. The Series B Preferred Stock is non-convertible, non-redeemable and non-retractable. It has superior liquidation rights to the common stock at \$0.10 per share and gives the holder the right to 1,000 votes per share. As of December 31, 2021 September 30, 2023 and December 31, 2022, 10,000 shares of the Series B Preferred Stock were outstanding and held by the CEO of the Company. Company's chief executive officer.

On February 17, 2022, the Company completed a public offering and received net proceeds of \$6,833,071 from the offering. Pursuant to the public offering, the Company issued and sold an aggregate of 1,882,353 shares of common stock and 4,102,200 warrants to purchase shares of common stock (the "Tradeable Warrants").

On February 22, 2022, the Company redeemed 990,000 shares of Series B Preferred Stock from the CEO of the Company at a redemption price equal to the stated value of \$0.10 per share. The remaining 10,000 shares of Series B Preferred Stock cannot be voted pursuant to a warrant agent agreement relating to the Tradeable Warrants (the "Warrant Agent Agreement"). On October 12, 2023, the Company held a special meeting of the holders of the outstanding Tradeable Warrants in which the holders of the majority of the outstanding Tradeable Warrants approved an amendment to the Warrant Agent Agreement which expires in February 2027, to eliminate the provision that prohibited the Company's CEO from exercising his voting rights under the Series B Preferred Stock, as well as to lower the exercise price of the Tradeable Warrants to \$0.11.

. The Company entered into the amendment to the Warrant Agent Agreement on October 18, 2023.

On March 14, 2022, the Company completed a private placement and received net proceeds of \$6,781,199. In connection with this private placement, the Company issued (i) 2,301,353 shares of its common stock together with investor warrants ("Investor Warrants") to purchase up to 2,301,353 shares of common stock, and (ii) 1,302,251 pre-funded warrants ("Pre-Funded Warrants") with each Pre-Funded Warrant exercisable for one share of common stock, together with Investor Warrants to purchase up to 1,302,251 shares of common stock. Each share of common stock and accompanying Investor Warrant was sold together at a combined offering price of \$2.22 and each Pre-Funded Warrant and accompanying Investor Warrant were sold together at a combined offering price of \$2.219. The Pre-Funded Warrants were immediately exercisable, at a nominal exercise price of \$0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Investor Warrants have an exercise price of \$2.22 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance.

On April 28, 2022, the Company completed another private placement and received net proceeds of \$16,752,915. In connection with this private placement, the Company issued (i) 2,472,820 shares of its common stock together with warrants ("April Warrants") to purchase up to 4,945,640 shares of common stock, and (ii) 2,390,025 pre-funded warrants ("Pre-Funded Warrants") with each Pre-Funded Warrant exercisable for one share of common stock, together with April Warrants to purchase up to 4,780,050 shares of common stock. Each share of common stock and accompanying two April Warrants were sold together at a combined offering price of \$4.01 and each Pre-Funded Warrant and accompanying two April Warrants were sold together at a combined offering price of \$4.009. The Pre-

Funded Warrants were immediately exercisable, at a nominal exercise price of \$0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The April Warrants have an exercise price of \$3.76 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance.

On October 20, 2022, the Company issued 3,700,000 shares of common stock as part of the acquisition of Nora Pharma. These shares were valued at \$4,514,000, or \$1.22 per share.

On January 19, 2023, the Company announced a stock repurchase program of up to \$2 million under SEC Rule 10B-18. ("Stock Repurchase Program"). During the six months ended June 30, 2023, the Company repurchased a total of 445,711 shares of common stock at an average price of \$1.1371 per share for a total cost of \$506,822. The 445,711 repurchased common shares were cancelled and returned to treasury reducing the number of issued and outstanding shares from 22,585,632 to 22,139,921.

On May 16, 2023, the Company completed a private placement pursuant to a securities purchase agreement with a single healthcare-focused institutional investor for gross proceeds of approximately \$5million, before deducting fees to the placement agent and other offering expenses payable by the Company. The net proceeds received by the Company were \$4,089,218. In connection with the private placement, the Company issued (i) 2,450,000shares of common stock, (ii) 3,502,381pre-funded warrants (the "May Pre-Funded Warrants"), and (iii) 11,904,762investor warrants (the "May Investor Warrants") to purchase up to 11,904,762 shares of common stock at \$0.59 per share. Each share of common stock and accompanying two May Investor Warrants were sold together at a combined offering price of \$0.84 and each May Pre-Funded Warrant and accompanying two May Investor Warrants were sold together at a combined offering price of \$0.839. The May Pre-Funded Warrants are immediately exercisable, at a nominal exercise price of \$0.001, and may be exercised at any time until all of the May Pre-Funded Warrants are exercised in full. The May Investor Warrants which have an exercise price of \$0.59 per share (subject to adjustment as set forth therein), are exercisable upon issuance and will expire five and a half years from the date of issuance.

In 2022 and the first six months of 2023, the Company issued a total of 10,789,867 shares of common stock in connection with warrant exercises for aggregate net proceeds of \$13,194,335.

In July 2023, the Company repurchased a total of 68,012 shares of common stock on the open market under the Stock Repurchase Program announced on January 19, 2023, at an average price of \$0.5046 per share for a total cost of \$34,321. In October 2023, the 68,012 repurchased common shares were cancelled and returned to treasury reducing the number of issued and outstanding shares from 25,746,302 to 25,678,290.

As of June 30, 2023 September 30, 2023 and December 31, 2022, the Company has a total of 25,746,302 25,678,290and 22,585,632shares of common stock issued and outstanding, respectively.

The Company has declared no dividends since inception.

Note 8 – Warrants

The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10 or ASC 815-40. Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC

815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.

In 2022 and during the first **six** **nine** months of 2023, the Company completed four financing events, and in connection therewith, it issued warrants as follows:

Type	Number	Exercise Price	Expiry Date	Number	Exercise Price	Expiry Date
Pre-Funded Warrants	3,692,276	\$0.001	Unlimited	3,692,276	\$0.001	Unlimited
Tradeable Warrants	4,102,200	\$2.22*	February 2027	4,102,200	\$2.22*	February 2027
Investor Warrants	3,603,604	\$2.22	March 2027	3,603,604	\$2.22	March 2027
April Warrants	9,725,690	\$3.76	April 2027	9,725,690	\$3.76	April 2027
May Pre-Funded Warrants	3,502,381	\$0.001	Unlimited	3,502,381	\$0.001	Unlimited
May Investor Warrants	11,904,762	\$0.59	November 2028	11,904,762	\$0.59	November 2028

*The Tradeable Warrants had an initial exercise price of \$4.25, subject to adjustment. Upon the closing of the Company's private placement on March 14, 2022, the exercise price of the Tradeable Warrants was reduced to \$2.22, in accordance with the terms thereof.

As of **June 30, 2023** **September 30, 2023**, all of the Pre-Funded Warrants and a total of 3,138,507 Tradeable Warrants, 2,802,703 Investor Warrants, and 1,156,381 May Pre-Funded Warrants were exercised resulting in aggregate proceeds of \$13,194,335 received by the Company.

The Company's outstanding warrants at **June 30, 2023** **September 30, 2023** consisted of the following:

Type	Number	Exercise Price	Expiry Date	Number	Exercise Price	Expiry Date
Pre-Funded Warrants	None	\$0.001	Unlimited	None	\$0.001	Unlimited
Tradeable Warrants	963,693	\$2.22	February 2027	963,693	\$2.22*	February 2027
Investor Warrants	800,901	\$2.22	March 2027	800,901	\$2.22	March 2027
April Warrants	9,725,690	\$3.76	April 2027	9,725,690	\$3.76	April 2027
May Pre-Funded Warrants	2,346,000	\$0.001	Unlimited	2,346,000	\$0.001	Unlimited

May Investor Warrants	11,904,762	\$0.59	November 2028	11,904,762	\$0.59	November 2028
----------------------------------	-------------------	---------------	--------------------------	-------------------	---------------	--------------------------

* On October 12, 2023, the Company held a special meeting of the holders of its outstanding Tradeable Warrants in which a majority of the holders approved an amendment to the Warrant Agent Agreement to reduce the exercise price of the Tradeable Warrants to \$0.11 per warrant. The amendment was executed on October 18, 2023.

Note 9 – Net Loss Per Common Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents.

Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, taking into consideration common stock equivalents.

In February 2022, the Company issued 4,102,200 Tradeable Warrants pursuant to the Company's Public Offering. In March and April 2022, the Company issued 3,603,604 Investor Warrants and 9,725,690 April Warrants pursuant to two private placements. In May 2023, the Company issued 11,904,762 May Investor Warrants pursuant to two private placements. As of **June 30, 2023** **September 30, 2023**, 3,138,507 Tradeable Warrants and 2,802,703 Investor Warrants were exercised, leaving 963,693 Tradeable Warrants, 800,901 Investor Warrants, 9,725,690 April Warrants, and 11,904,762 May Investor Warrants outstanding. These warrants are dilutive and were included in the diluted earnings per share.

In March and April 2022, the Company issued and sold Pre-Funded Warrants to purchase an aggregate of 3,692,276 shares of common stock at a nominal exercise price of \$0.001 per share. During the **six** **nine** months ended **June 30, 2023** **September 30, 2023**, all of these warrants were exercised and therefore had no remaining dilutive effect.

In May 2023, the Company issued and sold May Pre-Funded Warrants to purchase an aggregate of 3,502,381 shares of common stock at a nominal exercise price of \$0.001 per share. During the **six** **nine** months ended **June 30, 2023** **September 30, 2023**, 1,156,381 of these warrants were exercised leaving 2,346,000 outstanding. These warrants are dilutive and were not included in the diluted earnings per share calculation of weighted average outstanding shares as they would be ant-dilutive.

Note 10 – Lease

The Company has obligations as a lessee for office space with initial non-cancellable terms in excess of one year. The Company classified the lease as an operating lease. The lease contains a renewal option for a period of five years. Because the Company is certain to exercise the renewal option, the optional period is included in determining the lease term, and associated payments under the renewal option are included in the lease payments. The Company's lease does not include termination options for either party to the lease or restrictive financial or other covenants. Payments due under the lease contract include fixed payments plus a variable Payment. The Company's office space lease requires it to make variable payments for the Company's proportionate share of building's property taxes, insurance, and common area maintenance. These variable lease payments are not included in lease payments used to determine lease liability and are recognized as variable costs when incurred.

Amounts reported on the balance sheet as of **June 30, 2023** **September 30, 2023** were as follows:

Operating lease ROU asset	\$711,059	664,296
Operating Lease liability - Short-term	\$122,146	117,840
Operating lease liability - Long-term	\$596,850	555,687
Remaining lease term	6 years	63 months
Discount rate		6%

Amounts disclosed for ROU assets obtained in exchange for lease obligations and reductions of ROU assets resulting from reductions of lease obligations include amounts reduced from the carrying amount of ROU assets resulting from deferred rent.

Maturities of lease liabilities under non-cancellable operating leases at June 30, 2023 are as follows:

2023	\$61,987
2024	\$118,545
2025	\$118,737
2026	\$112,463
2027	\$105,930
Thereafter	\$201,335

Maturities of lease liabilities under non-cancellable operating leases at September 30, 2023 are as follows:

2023	\$ 30,124
2024	116,090
2025	116,277
2026	110,134
2027	103,736
Thereafter	197,166

Note 11 – Management and Director Compensation

The Company paid its officers cash compensation totaling \$225,000 245,000 and \$240,000 362,500 and \$1,045,000 1,290,000 and \$510,000 770,095 for the three and six-month nine-month periods ended June 30, 2023 September 30, 2023 and 2022, respectively.

The Company paid its directors cash compensation totaling \$100,000 and \$50,000 300,000 and \$100,000 and \$200,000 and \$50,000 for the three and six-month nine-month periods ended June 30, 2023 September 30, 2023 and 2022, respectively.

Note 12 – Income Taxes

In calculating the provision for income taxes on an interim basis, the Company uses an estimate of the annual effective tax rate based upon currently known facts and circumstances and applies that rate to its year-to-date earnings or losses. The Company's effective tax rate is based on expected income and statutory tax rates and takes into consideration permanent differences between financial statement and tax return income applicable to the Company in the various jurisdictions in which the Company operates. The effect of discrete items, such as changes in estimates, changes in rates or tax status, and unusual or infrequently occurring events, is recognized in the interim period in which the discrete item occurs. The accounting estimates used to compute the provision for income taxes may change as new events occur, additional information is obtained or as the result of new judicial interpretations or regulatory or tax law changes.

The Company's interim effective tax rate, inclusive of discrete items, for the three-month nine-month periods ended March 31, 2023 September 30, 2023 and 2022 was 26.83% 26.83%.

Note 13 – Subsequent Events

On January 19, 2023 October 12, 2023, the Company announced held a stock repurchase program special meeting of up the holders of its outstanding Tradeable Warrants in which the holders of the majority of the outstanding Tradeable Warrants approved an amendment to \$2 million the Warrant Agent Agreement to (i) reduce the exercise price of the Tradeable Warrants to \$0.11, subject to further adjustment as provided therein, and (ii) eliminate the provision that prohibits the Company's CEO from exercising his voting rights under his Series B Preferred Stock.

In December 2022, the Company had entered into a research agreement with the Jewish General Hospital ("JGH"), Montreal, Canada to conduct IND-enabling studies of the Company's anticancer drug candidate, Adva-27a (the "Research Agreement"). In July and August 2023, the Company repurchased a total of 68,012 shares of common stock at an average price of approximately \$0.5046 per share for a total cost of \$34,321. As was advised by JGH that the lab results on testing of the date Adva-27a molecule were not favorable. After conclusion of this report, an internal review

of the repurchased shares have not been returned lab results on November 2, 2023, the Company provided notice of termination of the Research Agreement, which will become effective on December 2, 2023, pursuant to treasury, the terms of the Research Agreement. The Company has now paused the IND-enabling studies of Adva-27a pending a review of the possibility of chemical modification of the compound to address the suboptimal performance of the molecule in certain studies.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with our consolidated financial statements and notes thereto included herein. This discussion includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. The statements regarding Sunshine Biopharma, Inc. contained in this Report that are not historical in nature, particularly those that utilize terminology such as "may," "will," "should," "likely," "expects," "anticipates," "estimates," "believes" or "plans," or comparable terminology, are forward-looking statements based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to us that could cause such material differences are identified in this report and in our annual report on Form 10-K for the year ended December 31, 2022. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law. You are advised, however, to consult any future disclosures we make on related subjects in future reports to the SEC.

About Sunshine Biopharma

We are a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. In addition to conducting pursuing our own drug development operations, program, we operate two wholly owned subsidiaries: (i) Nora Pharma Inc. ("Nora Pharma"), a Canadian corporation with a portfolio consisting of 50 51 generic prescription drugs on the market in Canada and 27 32 additional drugs scheduled to be launched during the next 18 months, in Canada in 2024 and 2025, and (ii) Sunshine Biopharma Canada Inc. ("Sunshine Canada"), a Canadian corporation which develops and sells nonprescription over-the-counter ("OTC") products.

History

We were incorporated in the State of Colorado on August 31, 2006, and on October 15, 2009, we acquired Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition.

Sunshine Biopharma, Inc. held an exclusive license to a new anticancer drug bearing the laboratory name, Adva-27a (the "License Agreement"). Upon completion of the reverse acquisition transaction, we changed our name to Sunshine Biopharma, Inc. and began operating as a pharmaceutical company.

In December 2015, we acquired all worldwide issued (US Patent Number 8,236,935, and 10,272,065) and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 for the Adva-27a anticancer compound and terminated the License Agreement.

In early 2020, we initiated a new R&D project focused on the development of a treatment for COVID-19 and on May 22, 2020, we filed a provisional patent application in the United States for the new coronavirus treatment. The patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease, Mpro. On April 30, 2021, we filed a PCT application containing new research results and extending coverage to include the Coronavirus Papain-Like protease, PLpro.

In June 2021, we initiated another R&D project in which we set out to determine if certain mRNA molecules can be used as anticancer agents. The data obtained for mRNA molecules bearing the laboratory name K1.1 became the subject of a new patent application filed in April 2022.

In October 2022, we acquired Nora Pharma, a Canadian generic pharmaceuticals company based in the greater Montreal area. Nora Pharma has 41 employees and operates in a 15,000 square foot facility certified by Health Canada. Nora Pharma currently sells 5051 generic prescription drugs in Canada. The consolidated financial statements contained in this report include the results of operations of Nora Pharma and Sunshine Canada.

Generic Prescription Drugs on the Market

As a result of the acquisition of Nora Pharma we now have the following generic prescription drugs on the market in Canada:

Drug	Action/Indication	Reference Brand
Alendronate	Osteoporosis	Fosamax®
Amlodipine	Cardiovascular	Norvasc®
Apixaban	Cardiovascular	Eliquis®
Atorvastatin	Cardiovascular	Lipitor®
Azithromycin	Antibacterial	Zithromax®
Candesartan	Hypertension	Atacand®
Candesartan HCTZ	Hypertension	Atacand® Atacand Plus®
Celecoxib	Anti-inflammatory	Celebrex®
Cetirizine	Allergy	Reactine®
Ciprofloxacin	Antibiotic	Cipro®
Citalopram	Central nervous system	Celexa®
Clindamycin	Antibiotic	Dalacin®
Clopidogrel	Cardiovascular	Plavix®
Dapagliflozin	Diabetes	Forxiga®
Donepezil	Central nervous system	Aricept®
Duloxetine	Central nervous system	Cymbalta®
Dutasteride	Urology	Avodart®
Escitalopram	Central nervous system	Cipralex®
Ezetimibe	Cardiovascular	Ezetrol®
Finasteride	Urology	Proscar®
Flecainide	Cardiovascular	Tambocor®
Fluconazole	Antifungal	Diflucan®
Fluoxetine	Central nervous system	Prozac®
Hydroxychloroquine	Antimalarial	Plaquenil®
Lacosamide	Central nervous system	Vimpat®
Letrozole	Oncology	Femara®
Levetiracetam	Central nervous system	Keprra®
Mirtazapine	Central nervous system	Remeron®
Metformin	Diabetes	Glucophage®
Montelukast	Allergy	Singulair®
Olanzapine ODT	Central nervous system	Zyprexa®
Olmesartan	Cardiovascular	Olmetec®
Olmesartan HCTZ	Cardiovascular	Olmetec Plus®
Pantoprazole	Acid Reflux Gastroenterology	Pantoloc®

Paroxetine	Central nervous system	Paxil®
Perindopril	Cardiovascular	Coversyl®
Pravastatin	Cardiovascular	Pravachol®
Pregabalin	Central nervous system	Lyrica®
Quetiapine	Central nervous system	Seroquel®
Quetiapine XR	Central nervous system	Seroquel XR®
Ramipril	Cardiovascular	Altace®
Rizatriptan ODT	Central nervous system	Maxalt® ODT
Rosuvastatin	Cardiovascular	Crestor®
Sertraline	Central nervous system	Zoloft®
Sildenafil	Urology	Viagra®
Tadalafil	Urology	Cialis®
Telmisartan	Cardiovascular	Micardis®
Telmisartan HCTZ	Cardiovascular	Micardis Plus®
Topiramate	Anticonvulsant	Topamax®
Tramadol Acetaminophen	Central nervous system	Tramacet®
Zolmitriptan	Central nervous system	Zomig®
Zopiclone	Central nervous system	Imovane®

Generic Prescription Drugs Pipeline

In addition to the 50⁵¹ drugs on the market, we currently have the following roster of generic prescription drugs scheduled to be launched later this year in 2024 and in 2024: 2025:

Generic Drugs	Therapeutic Area(s)	Development Stage	Launch Date
Group A (7 ² Products)	Cardiovascular, CNS*	Under manufacturing	2024Q1
Group B (6 Products)	Oncology, Gastroenterology, CNS*	Under regulatory review	2024Q2
Group C (3 Products)	Central Nervous System, Gastrointestinal, Urology, Diabetes, CNS*	Under Regulatory Review	2023Q3
Group B (1 Product)	Oncology	Under Regulatory Review	2023Q4
Group C (8 Products)	Central Nervous System, Cardiovascular, Metabolism	Under Regulatory Review	2024Q1
Group D (5 Products)	Cardiovascular, Urology, Endocrinology	Under Regulatory Review	2024Q2
Group E (6 ¹⁶ Products)	Urology, Cardiovascular, Oncology, Anti-infectives, Anti-inflammatory, Diabetes, Gastroenterology, CNS*	Under Regulatory Review	2024Q3
		Soon to be under regulatory review	2025

* Central Nervous System

We believe the addition of these products to our existing portfolio will strengthen our presence in the Canadian generic drugs marketplace and provide us with greater access to pharmacies as we become more of a go-to supplier for every-day and specialty medicines.

Proprietary Drugs in Development

We are currently developing the following drug candidates:

Proprietary Drugs	Therapeutic Area	Development Stage	Launch Date
Adva-27a (Small Molecule)	Oncology (Pancreatic Cancer)	IND-Enabling Studies - Subsequent Events	TBD TBD*
K1.1 (mRNA LNP)	Oncology (Liver Cancer)	Animal Testing Preclinical	TBD TBD*
SBFM-PL4 (Small Molecule)	Antiviral (COVID-19)	Animal Testing Preclinical	TBD TBD*

* To be determined

Adva-27a Anticancer Drug

Adva-27a is a small molecule designed for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). We are the direct owner of all patents pertaining to Adva-27a including U.S. Patents Number 8,236,935 and 10,272,065.

Adva-27a is a GEM-difluorinated C-glycoside derivative of Podophyllotoxin. Another derivative of Podophyllotoxin called Etoposide is currently on the market and is used to treat various types of cancer including leukemia, lymphoma, testicular cancer, lung cancer, brain cancer, prostate cancer, bladder cancer, colon cancer, ovarian cancer, liver cancer and several other forms of cancer. Etoposide is one of the most widely used anticancer drugs. Adva-27a and Etoposide are similar in that they both attack the same target in cancer cells, namely the DNA unwinding enzyme, Topoisomerase II. Unlike Etoposide however, Adva-27a has the advantage of being able to penetrate and destroy Multidrug Resistant Cancer cells. In addition, Adva-27a has been shown to have distinct and more desirable biological and pharmacological properties compared to Etoposide. In side-by-side studies using Multidrug Resistant Breast Cancer cells and Etoposide as a reference, Adva-27a showed markedly greater cell killing activity (see Figure 1).

Figure 1

In December 2022, we entered into a research agreement with the Jewish General Hospital ("JGH"), to conduct the IND-enabling studies of Adva-27a (the "Research Agreement"). In August 2023, we were informed by the JGH that the lab results on testing of the Adva-27a molecule were not favorable. After conclusion of an internal review of the lab results on November 2, 2023, we provided notice to JGH of termination of the Research Agreement. We have now paused the IND-enabling studies of Adva-27a pending a review of the possibility of chemical modification of the compound to address the suboptimal performance of the molecule in certain studies.

1918

In February 2023, we signed a research agreement with the Jewish General Hospital ("JGH"), to complete the IND-enabling studies. The JGH has also agreed to negotiate with us the terms for Phase I Clinical Trials. Adva-27a's initial indication will be pancreatic cancer for which there are currently little or no treatment options available. All aspects of the clinical trials in Canada will employ FDA standards at all levels.

K1.1 Anticancer mRNA

In June 2021, we initiated a new research project in which we set out to determine if certain mRNA molecules can be used as anti-cancer agents. The data collected to date have shown that a selected group of mRNA molecules are capable of destroying cancer cells *in vitro* including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Studies using non-transformed (normal) human cells (HMEC cells) showed that these mRNA molecules had little cytotoxic effects. These new mRNA molecules, bearing the laboratory name K1.1, are readily adaptable for delivery into patients using the mRNA vaccine technology. In April 2022, we filed a provisional patent application in the United States covering the subject mRNA molecules.

We recently concluded an agreement with a specialized partner for the purposes of formulating our K1.1 mRNA molecules into lipid nanoparticles, ready for use to conduct studies in xenograft mice. We anticipate commencing such studies later this year.

SBFM-PL4 Coronavirus Treatment

The initial genome expression products following infection by Betacoronavirus, the causative agent of COVID-19, are two large polyproteins, referred to as pp1a and pp1ab. These two polyproteins are cleaved at 15 specific sites by two virus encoded proteases, called Mpro and PLpro, to generate 16 different non-structural proteins essential for viral replication. Mpro and PLpro represent attractive anti-viral drug development targets as they play a central role in the early stages of viral replication. PLpro is of particular interest as a therapeutic target in that, in addition to processing essential viral proteins, it is also responsible for suppression of the human immune system making the virus more life-threatening. PLpro is present only in Betacoronaviruses, the subgroup of Coronaviruses represented by the highly pathogenic SARS-CoV, MERS-CoV, and SARS-CoV-2.

Our Anti-Coronavirus research effort has been focused on developing an inhibitor of PLpro and, on May 22, 2020, we filed a patent application in the United States covering composition subject matter pertaining to small molecules for inhibition of the Coronavirus PLpro as well as Mpro.

In February 2022, we expanded our PLpro inhibitors research effort by entering into a research agreement with the University of Arizona for the purposes of conducting research focused on determining the *in vivo* safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro inhibitors, to be followed by efficacy testing in mice infected with SARS-CoV-2 (the "Research Project"). Under the agreement, the University of Arizona granted the Company a first option to negotiate a commercial, royalty-bearing license for all intellectual property developed by University of Arizona under the Research Project. In addition, the Company and the University of Arizona entered into an option agreement (the "Option Agreement") whereby the Company was granted a first option to negotiate a royalty-bearing commercial license for the underlying technology of the Research Project. On September 13, 2022, we exercised our options, and on February 24, 2023, we entered into an exclusive worldwide license agreement with the University of Arizona for all of the technology related to the Research Project.

With the evolution of the COVID-19 pandemic to its current state, we have recently expanded our objective to develop a late-preclinical include the development of an injectable candidate of first-in-class PLpro inhibitor to treat SARS-CoV2 (and potentially SARS-CoV and MERS-CoV) infection in patients who could not use Paxlovid, Molnupiravir, or Remdesivir, due to concerns about drug interaction and possible 'rebound' infections and other side effects.

2019

Intellectual Property

We are the sole owner of all worldwide rights pertaining to Adva-27a. These patent rights are covered by PCT/FR2007/000697 and PCT/CA2014/000029. The patent applications filed under these two PCT's have been issued in the United States (US Patent Number 8,236,935 and 10,272,065), Europe, and Canada.

On May 22, 2020, we filed a provisional patent application in the United States for a new treatment for Coronavirus infections. Our patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease, Mpro, an enzyme that is essential for viral replication. The patent application has a priority date of May 22, 2020. On April 30, 2021, we filed a PCT application containing new research results and extending coverage to include the Coronavirus Papain-Like protease, PLpro. The priority date of May 22, 2020 has been maintained in the newly filed PCT application.

On April 20, 2022, we filed a provisional patent application in the United States covering mRNA molecules capable of destroying cancer cells in vitro. The patent application contains composition and utility subject matter pertaining to the structure and sequence of the relevant mRNA molecules.

Our recently acquired wholly owned subsidiary, Nora Pharma, owns 179180 Drug Identification Numbers ("DIN's") issued by Health Canada for prescription drugs currently on the market in Canada. These DIN's were secured through in-licenses or cross-licenses from international manufacturers of generic pharmaceutical products.

In addition, we are the owner of two Natural Product Numbers ("NPN's") issued by Health Canada: NPN 80089663 authorizes us to manufacture and sell our in-house developed OTC product, Essential 9™, and NPN 80093432 authorizes us to manufacture and sell the OTC product, Calcium-Vitamin D under the brand name Essential Calcium-Vitamin D™.

Results of Operations

Comparison of results of operations for the three months ended June 30, 2023 September 30, 2023 and 2022

During the three months ended June 30, 2023 September 30, 2023, we generated \$5,560,865 \$5,957,668 in sales, compared to \$150,307 \$132,808 for the three months ended June 30, 2022 September 30, 2022, an increase of \$5,410,558. The increase is attributable to sales generated by our wholly owned subsidiary, Nora Pharma. The direct cost for generating these sales was \$3,967,412 (66.6%) for the three months ended September 30, 2023, compared to \$65,783 (49.5%) for the three months ended September 30, 2022. The increase in the cost of goods sold in 2023 is due to increased cost of manufacturing of the generic prescription drugs sold by Nora Pharma. Our gross profit grew to \$1,990,256 for the three months ended September 30, 2023, compared to \$67,025 for the three months ended September 30, 2022.

General and administrative expenses during the three-month period ended September 30, 2023, were \$2,769,730, compared to \$1,785,005 during the three-month period ended September 30, 2022, an increase of \$984,725. This increase was the result of increased overhead associated with being a Nasdaq listed company and expenses related to Nora Pharma operations. Specifically, we incurred increased costs in consulting (\$58,929), office (\$467,397), salaries (\$549,377) and taxes (\$52,586). Overall, we incurred a loss of \$779,474 from our operations for the three months ended

September 30, 2023, compared to a loss of \$1,717,980 from our operations in the three-month period ended September 30, 2022.

In addition, we had net interest income of \$168,904 during the three months ended September 30, 2023, compared to a net interest income of approximately \$260,936 during the three months ended September 30, 2022, as a result of interest earned on cash on hand.

As a result, we incurred a net loss of \$651,482 (\$0.04 per share) for the three months ended September 30, 2023, compared to a net loss of \$1,457,019 (\$0.08 per share) for the three-month period ended September 30, 2022.

Comparison of results of operations for the nine months ended September 30, 2023 and 2022

During the nine months ended September 30 2023, we generated revenues of \$16,412,586, compared to revenues of \$405,760 for the nine months ended September 30, 2022, an increase of \$16,006,826. The increase is attributable to sales generated by our recently acquired wholly owned subsidiary, Nora Pharma. The direct cost for generating these sales revenues was \$3,608,118 (64.9% \$10,641,461 (64.8%) for the three nine months ended June 30, 2023 September 30, 2023, compared to \$74,683 (49.7% \$200,311 (49.4%) for the three nine months ended June 30, 2022 September 30, 2022. The increase in the cost of goods sold in 2023 is due to the increased cost of manufacturing of the generic prescription drugs sold by Nora Pharma. Our gross profit grew increased to \$1,952,747 \$5,771,125 for the three nine months ended June 30, 2023 September 30, 2023, compared to \$75,624 a gross profit of \$205,449 for the three months ended June 30, 2022, same period in 2022.

General and administrative expenses during the three-month nine-month period ended June 30, 2023 September 30, 2023 were \$2,942,370, \$9,369,203 compared to \$771,420 \$3,842,589 during the three-month nine-month period ended June 30, 2022 September 30, 2022, an increase of \$2,170,950. \$5,526,614. This increase was the result of increased overhead associated with being a Nasdaq listed company and expenses related to Nora Pharma operations. Specifically, we incurred increased costs in accounting (\$34,221) 63,608), consulting (\$290,771) 475,817), office costs (\$304,978) 972,328), research and development (\$322,622) 269,407), salaries (\$960,167) 3,239,801) and taxes (\$96,649) 212,953). Overall, we incurred a loss of \$989,623 from our operations for the three months ended June 30, 2023, compared to a loss of \$695,796 \$3,598,078 from our operations in the three-month nine-month period ended June 30, 2022.

In addition, we had net interest income of approximately \$175,453 during the three months ended June 30, 2023, compared to a net interest income of approximately \$146,043 during the three months ended June 30, 2022, as a result of interest earned on cash on hand.

As a result, we incurred a net loss of \$902,108 (\$0.02 per share) for the three months ended June 30, 2023, compared to a net loss of \$538,872 (\$0.03 per share) for the three-month period ended June 30, 2022.

Comparison of results of operations for the six months ended June 30, 2023 and 2022

During the six months ended June 30 2023, we generated revenues of \$10,454,918, compared to revenue of \$272,952 for the six months ended June 30, 2022, an increase of \$10,181,966. The increase is attributable to sales generated by our recently acquired wholly owned subsidiary, Nora Pharma. The direct cost for generating these revenues was \$6,674,049 for the six months ended June 30, 2023 (63.8%), compared to \$134,528 (49.3%) for the six months ended June 30, 2022. The increase in the cost of goods sold in 2023 is due to the cost of manufacturing the generic prescription drugs sold by Nora Pharma. Our gross profit increased to \$3,780,869 for the six months ended June 30, 2023, compared to a gross profit of \$138,424 for the same period in 2022.

General and administrative expenses during the six-month period ended June 30, 2023 were \$6,599,473 compared to \$2,057,584 during the six-month period ended June 30, 2022, an increase of \$4,541,889. This increase was the result of increased overhead associated with being a Nasdaq listed company and expenses related to Nora Pharma operations. Specifically, we incurred increased costs in accounting (\$130,171), consulting (\$416,888), office costs (\$504,931), research and development (\$393,895), salaries (\$2,640,424) and taxes (\$160,367). Overall, we incurred a loss of \$2,818,604 from our operations in the six-month period ended June 30, 2023 September 30, 2023, compared to a loss from operations of \$1,919,160 \$3,637,140 in the similar period of 2022.

In addition, we had net interest income of approximately \$348,259 \$517,163 during the six nine months ended June 30, 2023 September 30, 2023, compared to a net interest income of approximately \$133,182 \$394,118 during the six nine months ended June 30, 2022 September 30, 2022, as a result of interest earned on cash on hand.

As a result, we incurred a net loss of \$2,604,538 \$3,256,020 (\$0.09 0.12 per share) for the six-month nine-month period ended June 30, 2023 September 30, 2023, compared to a net loss of \$1,775,106 \$3,232,125 (\$0.18 0.26 per share) for the six-month nine-month period ended June 30, 2022 September 30, 2022.

Liquidity and Capital Resources

As of June 30, 2023 September 30, 2023, we had cash or cash equivalents of \$19,729,491. \$18,846,140.

Net cash used in operating activities was \$5,628,146 \$6,085,435 during the six nine months ended June 30, 2023 September 30, 2023, compared to \$1,878,010 \$3,001,746 during the six-month nine-month period ended June 30, 2022 September 30, 2022. The increase was a result of the addition of Nora Pharma's operations.

Cash flows used in investing activities were \$405,779 \$386,920 for the six nine months ended June 30, 2023 September 30, 2023, compared to \$0 for the six nine months ended June 30, 2022 September 30, 2022. The increase was the result of cash invested in Nora Pharma.

Cash flows provided by financing activities were \$3,519,672 \$3,456,106 during the six nine months ended June 30, 2023 September 30, 2023, compared to \$41,561,363 during the six nine months ended June 30, 2022 September 30, 2022. The decrease was primarily as a result of one offering made during the six nine months ended June 30, 2023 September 30, 2023, compared to three offerings completed in February, March, and April 2022, and due to our purchase repurchase of \$506,822 a total of \$540,629 in common stock in the first and third quarter of 2023.

We are not generating adequate revenues from our operations to fully implement our business plan as set forth herein. On February 17, 2022, we received net proceeds of approximately \$6.8 million from the sale of common stock and warrants in an underwritten public offering. On March 14, 2022, we received net proceeds of approximately \$6.8 million from the sale of common stock and warrants in a private placement. On April 28, 2022, we received net proceeds of approximately \$16.8 million from the sale of common stock and warrants in a private placement. On May 16, 2023, we received net proceeds of approximately \$4.1 million from the sale of common stock and warrants in a private placement. We believe our existing cash will be sufficient to fund our operations, including general and administrative expenses, research and development activities, and the generic pharmaceuticals sales business, for the next 18 to 24 months. There is no assurance our estimates will be accurate.

Management estimates that we will need additional capital in the amount of approximately \$30 million for expansion of our drug development activities and generic pharmaceuticals operations, including possibly a Phase I clinical trial. Additional capital may not be available on terms acceptable to us, or at all. Currently, we do not have any firm committed arrangements for financing and can provide no assurance that we will be able to obtain financing when required. No assurance can be given that we will obtain access to capital markets in the future or that financing, adequate to satisfy the cash requirements of implementing our business will be available on acceptable terms. Our inability to obtain acceptable financing could have an adverse effect upon the results of our operations and financial condition.

Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

For a detailed list of significant accounting policies, please see our annual report on Form 10-K for the fiscal year ended December 31, 2022, including our financial statements and notes thereto included therein as filed with the SEC on April 4, 2023.

Recently Adopted Accounting Standards

In February 2020, the FASB issued ASU 2020-02, Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842) which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. The Company believes the adoption will modify the way the Company analyzes financial instruments, but it does not anticipate a material impact on results of operations. The Company is in the process of determining the effects adoption will have on its consolidated financial statements.

In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity's Own Equity (Subtopic 815 – 40), ("ASU 2020-06"). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity's own equity. The ASU 2020-06 amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is evaluating the impact of this guidance on its unaudited consolidated financial statements.

Off Balance-Sheet Arrangements

None.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company and are not required to provide the information under this item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report.

These controls are designed to ensure that information required to be disclosed in the reports we file or submit pursuant to the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our CEO and CFO, to allow timely decisions regarding required disclosure.

Based on this evaluation, our management, including our CEO and CFO concluded that our disclosure controls and procedures were effective as of **June 30, 2023** **September 30, 2023**, at reasonable assurance levels.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended **June 30, 2023** **September 30, 2023**, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are not party to, and our property is not the subject of, any material legal proceedings.

ITEM 1A. RISK FACTORS

We are a smaller reporting company and are not required to provide the information under this item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibit No.	Description
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2022*
32.1	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
101	Inline XBRL Document Set for the financial statements and accompanying notes in Part I, Item 1, of this Quarterly Report on Form 10-Q.*
104	Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.*

* Filed herewith.

** Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized, on **August 10, 2023** **November 13, 2023**.

SUNSHINE BIOPHARMA, INC.

By: /s/ Dr. Steve N. Slilaty

Dr. Steve N. Slilaty

Chief Executive Officer (principal executive officer)

By: /s/ Camille Sebaaly

Camille Sebaaly

Chief Financial Officer (principal financial and accounting officer)

26

Exhibit 31.1

CERTIFICATION PURSUANT TO 18 USC, SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Dr. Steve N. Slilaty, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Sunshine Biopharma, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: August 10, 2023 November 13, 2023

/s/ Dr. Steve N. Slilaty

Dr. Steve N. Slilaty, Chief Executive Officer

Exhibit 31.2

**CERTIFICATION PURSUANT TO
18 USC, SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES OXLEY ACT OF 2002**

I, Camille Sebaaly, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Sunshine Biopharma, Inc.
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

- a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: **August 10, 2023** **November 13, 2023**

/s/ Camille Sebaaly

Camille Sebaaly, Chief Financial Officer

Exhibit 32.1

**CERTIFICATION PURSUANT TO
18 USC, SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with this quarterly report of Sunshine Biopharma, Inc. (the "Company") on Form 10-Q for the quarterly period ended **June 30, 2023 **September 30, 2023**, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), we, the undersigned, in the capacities and on the date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:**

1. The Report fully complies with the requirements of Rule 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: **August 10, 2023** **November 13, 2023**

/s/ Dr. Steve N. Slilaty

Dr. Steve N. Slilaty, Chief Executive Officer

Dated: **August 10, 2023** **November 13, 2023**

/s/ Camille Sebaaly

Camille Sebaaly, Chief Financial Officer

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2023, Refinitiv. All rights reserved. Patents Pending.